Home Cannabinoid GW Pharmaceuticals Announce FDA Approval of EPIDIOLEX® (cannabidiol) Oral Solution

GW Pharmaceuticals Announce FDA Approval of EPIDIOLEX® (cannabidiol) Oral Solution

267
0
ADravet Syndrome Foundation, is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. it affects 1:15,700 individuals, 80% of whom have a mutation in their SCN1A gene [1]. “While seizures persist, other comorbidities such as developmental delay and abnormal EEGs are often not evident until the second or third year of life” according to Dravet syndrome Foundation.
A severe form of epilepsy, Lennox-Gastaut that begins in childhood.  It is often accompanied with a myriad of seizures in addition to intellectual disability. The ailment typically surfaces at childhood–between ages 3 to 5 years old.
It was reported by SandHills Express.com that “Epidolex, a medication formulated from a cannabidiol (CBD) substance derived from the marijuana plan was approved by the US FDA for children and adults over the age of 2.”
Epidiolex, a medication formulated from a cannabidiol (CBD) substance derived from the marijuana plant was approved by the U.S. Food and Drug Administration (FDA) for children and adults over the age of 2.

View article here

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.